Background:The effect of perioperative injection of Lucentis on intraoperative bleeding in patients with proliferative diabetic retinopathy(PDR) was systematically evaluated using a meta-analysis.Methods: Reports of s...Background:The effect of perioperative injection of Lucentis on intraoperative bleeding in patients with proliferative diabetic retinopathy(PDR) was systematically evaluated using a meta-analysis.Methods: Reports of surgical eye treatment with and without perioperative intravitreal injection of Lucentis in Medline, the Cochrane Library, Pub Med, the Chinese Biomedical Literature Database, and China Academic Journals Full-text Database were included in the study. A meta-analysis was performed on all included literature. A computerized search was performed in the above databases. In addition, relevant books, journals, and conference proceedings and their bibliographies were manually searched. Published literature was screened according to the inclusion and exclusion criteria. Data extraction was performed on included studies. RevMan 5.2 software was used for the statistical analyses. Dichotomous variables are presented as odds ratios(ORs) and 95% confidence intervals(CIs). The major indicator was the occurrence of intraoperative retinal hemorrhaging during vitrectomy.Results: A total of seven studies were included in the analysis. The treatment group included 159 eyes and control group included 149 eyes. The amount of intraoperative bleeding in the treatment group(perioperative Lucentis injection) was significantly lower than that in the control group(OR, 56.93; 95% CI: 21.81-148.57, P<0.01).Conclusions: Intravitreal Lucentis injection before a vitrectomy significantly reduced intraoperative bleeding in PDR patients.展开更多
目的:探讨玻璃体腔注射康柏西普联合23G微创玻璃体切割术治疗对增殖性糖尿病视网膜病变(PDR)患者视网膜出血、视网膜增殖及视力预后的影响。方法:将我院收治的56例56眼PDR患者分为康柏西普联合微创玻璃体切割术(pars plana vitrectomy,P...目的:探讨玻璃体腔注射康柏西普联合23G微创玻璃体切割术治疗对增殖性糖尿病视网膜病变(PDR)患者视网膜出血、视网膜增殖及视力预后的影响。方法:将我院收治的56例56眼PDR患者分为康柏西普联合微创玻璃体切割术(pars plana vitrectomy,PPV)组和PPV组,各28例,康柏西普组给予玻璃体腔内注射康柏西普+23G微创玻璃体切割术,PPV组仅给予23G微创玻璃体切割术,比较两组手术时间、视网膜出血、视网膜增殖、视力等情况。结果:康柏西普联合PPV组手术耗时及术中出血量均明显低于PPV组(P<0.05);康柏西普联合PPV组术后视力、黄斑厚度均显著优于PPV组(P<0.05);康柏西普联合PPV组术后视网膜出血评分、视网膜增殖评分、玻璃体再次出血率及血管内皮生长因子(VEGF)水平均显著低于PPV组(P<0.05)。结论:玻璃体腔注射康柏西普联合23G微创玻璃体切割术治疗PDR不仅能有效缩短手术时间,减少术中视网膜出血和术后再出血,减轻视网膜增殖,还有助于患者术后视力恢复。展开更多
文摘Background:The effect of perioperative injection of Lucentis on intraoperative bleeding in patients with proliferative diabetic retinopathy(PDR) was systematically evaluated using a meta-analysis.Methods: Reports of surgical eye treatment with and without perioperative intravitreal injection of Lucentis in Medline, the Cochrane Library, Pub Med, the Chinese Biomedical Literature Database, and China Academic Journals Full-text Database were included in the study. A meta-analysis was performed on all included literature. A computerized search was performed in the above databases. In addition, relevant books, journals, and conference proceedings and their bibliographies were manually searched. Published literature was screened according to the inclusion and exclusion criteria. Data extraction was performed on included studies. RevMan 5.2 software was used for the statistical analyses. Dichotomous variables are presented as odds ratios(ORs) and 95% confidence intervals(CIs). The major indicator was the occurrence of intraoperative retinal hemorrhaging during vitrectomy.Results: A total of seven studies were included in the analysis. The treatment group included 159 eyes and control group included 149 eyes. The amount of intraoperative bleeding in the treatment group(perioperative Lucentis injection) was significantly lower than that in the control group(OR, 56.93; 95% CI: 21.81-148.57, P<0.01).Conclusions: Intravitreal Lucentis injection before a vitrectomy significantly reduced intraoperative bleeding in PDR patients.
文摘目的:探讨玻璃体腔注射康柏西普联合23G微创玻璃体切割术治疗对增殖性糖尿病视网膜病变(PDR)患者视网膜出血、视网膜增殖及视力预后的影响。方法:将我院收治的56例56眼PDR患者分为康柏西普联合微创玻璃体切割术(pars plana vitrectomy,PPV)组和PPV组,各28例,康柏西普组给予玻璃体腔内注射康柏西普+23G微创玻璃体切割术,PPV组仅给予23G微创玻璃体切割术,比较两组手术时间、视网膜出血、视网膜增殖、视力等情况。结果:康柏西普联合PPV组手术耗时及术中出血量均明显低于PPV组(P<0.05);康柏西普联合PPV组术后视力、黄斑厚度均显著优于PPV组(P<0.05);康柏西普联合PPV组术后视网膜出血评分、视网膜增殖评分、玻璃体再次出血率及血管内皮生长因子(VEGF)水平均显著低于PPV组(P<0.05)。结论:玻璃体腔注射康柏西普联合23G微创玻璃体切割术治疗PDR不仅能有效缩短手术时间,减少术中视网膜出血和术后再出血,减轻视网膜增殖,还有助于患者术后视力恢复。
